Understanding how neutrophils affect vaccine responses in aging adults
The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
This study is testing how certain immune cells called neutrophils affect the response to the Prevnar-13 vaccine in older adults compared to younger ones, to see if it can help improve vaccine effectiveness for seniors.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | State University of New York at Buffalo Academic / other |
| Locations | 1 site (Buffalo, New York) |
| Trial ID | NCT06128915 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of neutrophils in the immune response to the Prevnar-13 vaccine in both young and elderly adults. It involves direct vaccination of participants and aims to assess how neutrophils respond to the vaccine, including their ability to kill bacteria and interact with other immune cells. Key endpoints include measuring antibody levels and correlating neutrophil activity with these antibody responses before and after vaccination. The findings could provide insights into improving vaccine efficacy in older populations.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults aged 21-40 and those aged 65 and older who have not previously received any pneumococcal vaccine.
Not a fit: Patients with known immune deficiencies, chronic infections, or those who have been vaccinated with pneumococcal vaccines will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance vaccine responses in elderly individuals, leading to better protection against pneumococcal infections.
How similar studies have performed: While the specific role of neutrophils in vaccine responses among aging populations is less explored, similar studies have shown that understanding immune cell interactions can lead to improved vaccine strategies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Both sexes * Have not been vaccinated with any licensed or experimental pneumococcal vaccine * Ages 21-40; and ≥65. Individuals \>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old * Free of acute infections within the last 2 weeks * Did not take any anti-inflammatory medicine in the last week * Did not ingest alcohol in the last 24 hours * Ability and willingness to provide consent Exclusion Criteria: * Previous vaccination with any licensed or experimental pneumococcal vaccine * Known hypersensitivity to vaccination and vaccine components * Immune deficiency * Use of immune-modulating or suppressive drugs * Malignancies within the last 2 years * Known hematological, rheumatic and inflammatory diseases * Known chronic infections * Poorly controlled chronic cardiovascular and metabolic conditions * Pregnancy * Dementia
Where this trial is running
Buffalo, New York
- University at Buffalo — Buffalo, New York, United States (Recruiting)
Study contacts
- Principal investigator: Elsa N Bou Ghanem, PhD — University at Buffalo
- Study coordinator: Elsa Bou Ghanem, PhD
- Email: elsaboug@buffalo.edu
- Phone: 7168292422
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.